Jiangsu Hengrui Pharmaceuticals Co. $600276.SS, a prominent Chinese drug developer specializing in oncology and cardiovascular innovations, executed its secondary listing in Hong Kong by setting the share price at the upper limit. The company raised 9.9 billion Hong Kong dollars (approximately USD 1.3 billion), a capital infusion underlining the significant appetite for high-quality Chinese healthcare assets on the Hong Kong Stock Exchange.